Analyzing Intellipharmaceutics International (OTCMKTS:IPCIF) and Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ:OVID) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Earnings and Valuation

This table compares Ovid Therapeutics and Intellipharmaceutics International’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$390,000.00	561.03	-$52.34 million	($0.75)	-4.12
Intellipharmaceutics International	$660,000.00	5.01	-$2.89 million	($0.16)	-0.63

Intellipharmaceutics International has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Intellipharmaceutics International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Ovid Therapeutics and Intellipharmaceutics International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0	1	5	0	2.83
Intellipharmaceutics International	0	0	0	0	N/A

Ovid Therapeutics presently has a consensus target price of $8.08, suggesting a potential upside of 161.60%. Given Ovid Therapeutics’ higher probable upside, research analysts plainly believe Ovid Therapeutics is more favorable than Intellipharmaceutics International.

Profitability

This table compares Ovid Therapeutics and Intellipharmaceutics International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-13,351.53%	-49.76%	-38.16%
Intellipharmaceutics International	-344.25%	N/A	-200.63%

Institutional and Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Intellipharmaceutics International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Ovid Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Summary

Intellipharmaceutics International beats Ovid Therapeutics on 7 of the 13 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

About Intellipharmaceutics International

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.